[Current Diagnosis and Therapy of Osteoporosis on the Basis of "European Guidance 2008"]

Overview

Journal Orthopade

Specialty Orthopedics

Date 2009 Mar 24

PMID 19305966

Citations 4

Authors

R Bartl

R Gradinger

Affiliations

Soon will be listed here.

Abstract

Osteoporosis is one of the 10 most important and widespread global diseases. In Germany alone the cost of osteoporosis runs into many billions of Euros. However, it should be noted that in the past 15 years great progress has been made both in diagnosis and in the development of new medications, and this has changed the general perception of and attitude to osteoporosis. It is now taken very seriously and recognised as a national and global disorder which is both preventable and treatable. In spite of this progress, in Europe and especially in Germany, osteoporosis remains an underdiagnosed and undertreated disease. In Germany, only about 10%-15% of patients with manifest osteoporosis are properly treated. However, in addition to national guidelines, there is now a new edition of the "European Position Paper for the Diagnosis and Management of Osteoporosis". This provides physicians treating osteoporosis patients with additional information and therefore more confidence.

Citing Articles

Bisphosphonate conjugation for bone specific drug targeting.

Farrell K, Karpeisky A, Thamm D, Zinnen S Bone Rep. 2018; 9:47-60.

PMID: 29992180 PMC: 6037665. DOI: 10.1016/j.bonr.2018.06.007.

Does the cement stiffness affect fatigue fracture strength of vertebrae after cement augmentation in osteoporotic patients?.

Kolb J, Kueny R, Puschel K, Boger A, Rueger J, Morlock M Eur Spine J. 2013; 22(7):1650-6.

PMID: 23677522 PMC: 3698342. DOI: 10.1007/s00586-013-2809-2.

Effects of physical therapy on quality of life in osteoporosis patients - a randomized clinical trial.

Schroder G, Knauerhase A, Kundt G, Schober H Health Qual Life Outcomes. 2012; 10:101.

PMID: 22920839 PMC: 3511275. DOI: 10.1186/1477-7525-10-101.

[Secondary osteoporosis: pathogenesis, types, diagnostics and therapy].

Bartl C, Bartl R Radiologe. 2011; 51(4):307-24.

PMID: 21455799 DOI: 10.1007/s00117-011-2143-9.

References

Kanis J, Burlet N, Cooper C, Delmas P, Reginster J, Borgstrom F . European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008; 19(4):399-428. PMC: 2613968. DOI: 10.1007/s00198-008-0560-z. View

Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3):321-33. DOI: 10.1001/jama.288.3.321. View

Russell R, Watts N, Ebetino F, Rogers M . Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008; 19(6):733-59. DOI: 10.1007/s00198-007-0540-8. View

Reginster J, Seeman E, De Vernejoul M, Adami S, Compston J, Phenekos C . Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005; 90(5):2816-22. DOI: 10.1210/jc.2004-1774. View

Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Shea B . Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev. 2002; 23(4):540-51. DOI: 10.1210/er.2001-6002. View

Burge R, Dawson-Hughes B, Solomon D, Wong J, King A, Tosteson A . Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2006; 22(3):465-75. DOI: 10.1359/jbmr.061113. View

Watts N, Geusens P, Barton I, Felsenberg D . Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res. 2005; 20(12):2097-104. DOI: 10.1359/JBMR.050814. View

Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C . Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002; 23(4):570-8. DOI: 10.1210/er.2001-9002. View

Kanis J, Gluer C . An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int. 2000; 11(3):192-202. DOI: 10.1007/s001980050281. View

10.

Pazianas M, Blumentals W, Miller P . Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int. 2007; 19(6):773-9. PMC: 2358932. DOI: 10.1007/s00198-007-0547-1. View

11.

Bartl R . [Practical guidelines for the management of osteoporosis--evidence-based and cost-effective]. Dtsch Med Wochenschr. 2007; 132(18):995-9. DOI: 10.1055/s-2007-979369. View

12.

Johnell O, Kanis J . An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006; 17(12):1726-33. DOI: 10.1007/s00198-006-0172-4. View

13.

Delmas P, Rizzoli R, Cooper C, Reginster J . Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation. Osteoporos Int. 2004; 16(1):1-5. DOI: 10.1007/s00198-004-1813-0. View

14.

Dafonseca K, Baier M, Grafe I, Libicher M, Noeldge G, Kasperk C . [Balloon kyphoplasty in the therapy of vertebral fractures]. Orthopade. 2006; 35(10):1101-9. DOI: 10.1007/s00132-006-1005-z. View

15.

Lewiecki E, Watts N, McClung M, Petak S, Bachrach L, Shepherd J . Official positions of the international society for clinical densitometry. J Clin Endocrinol Metab. 2004; 89(8):3651-5. DOI: 10.1210/jc.2004-0124. View

16.

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

17.

Kanis J, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby A . The components of excess mortality after hip fracture. Bone. 2003; 32(5):468-73. DOI: 10.1016/s8756-3282(03)00061-9. View

18.

Chen P, Miller P, Delmas P, Misurski D, Krege J . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res. 2006; 21(11):1785-90. DOI: 10.1359/jbmr.060802. View

19.

Bruyere O, Roux C, Detilleux J, Slosman D, Spector T, Fardellone P . Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab. 2007; 92(8):3076-81. DOI: 10.1210/jc.2006-2758. View

20.

Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J . Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809-22. DOI: 10.1056/NEJMoa067312. View